Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 17/20 | 0.47 |
| ▸ | ITGAV | P06756 | 17/20 | 0.47 |
| ▸ | ITGB6 | P18564 | 6/20 | 0.47 |
| ▸ | ITGB5 | P18084 | 4/20 | 0.47 |
| ▸ | ITGB8 | P26012 | 2/20 | 0.47 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.47 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 8/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL274618 | 0.92 | ITGB3 (0.42) | ITGB3ITGAVITGB6ITGB5ITGB8 | |
| SCHEMBL328203 | 0.90 | ITGAV (0.48) | ITGB3ITGAVITGB6ITGB5ITGB8 | |
| SCHEMBL328202 | 0.89 | ITGAV (0.51) | ITGB3ITGAVITGB6ITGB5ITGB8 | |
| SCHEMBL328187 | 0.88 | ITGAV (0.48) | ITGB3ITGAVITGB6ITGB5ITGB8 | |
| SCHEMBL328032 | 0.88 | ITGB3 (0.48) | ITGB3ITGAVITGB6ITGB5ITGB8 | |
| SCHEMBL328007 | 0.88 | ITGAV (0.48) | ITGB3ITGAVITGB6ITGB5ITGB8 | |
| SCHEMBL13003788 | 0.86 | ITGAV (0.49) | ITGB3ITGAVITGB6ITGB5ITGB8 | |
| SCHEMBL10201953 | 0.86 | ITGAV (0.49) | ITGB3ITGAVITGB6ITGB5ITGB8 | |
| SCHEMBL327992 | 0.84 | ITGAV (0.51) | ITGB3ITGAVITGB6ITGB5ITGB8 | |
| SCHEMBL13003793 | 0.83 | ITGAV (0.50) | ITGB3ITGAVITGB6ITGB5ITGB8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765766-B2 | Pyrimidine derivatives which are antagonists of the vitronectin receptor | GALAPAGOS NV (BE) | 2014-07-01 | — | — | US | disclosed |
| EP-1747222-B1 | PYRIMIDINE DERIVATIVES ANTAGONISTS OF VITRONECTIN RECEPTOR | GALAPAGOS NV (BE) | 2014-04-16 | — | — | EP | disclosed |
| EP-2368891-B1 | Pyrimidines derivatives as antagonists of the vitronectine receptors | GALAPAGOS NV (BE) | 2012-09-19 | — | — | EP | disclosed |
| US-20120115883-A1 | PYRIMIDINE DERIVATIVES WHICH ARE ANTAGONISTS OF THE VITRONECTIN RECEPTOR | GALAPAGOS SAS | 2012-05-10 | — | — | US | disclosed |
| US-8133896-B2 | Pyrimidine derivatives which are antagonist of the vitronectin receptor | GALAPAGOS NV (BE) | 2012-03-13 | — | — | US | disclosed |
| EP-2368891-A1 | Pyrimidines derivatives as antagonists of the vitronectine receptors | Galapagos SAS (FR) | 2011-09-28 | — | — | EP | disclosed |
| US-20110039867-A1 | PYRIMIDINE DERIVATIVES WHICH ARE ANTAGONIST OF THE VITRONECTIN RECEPTOR | GALAPAGOS SAS | 2011-02-17 | — | — | US | disclosed |
| US-7846932-B2 | treatment of retinopathy comprising administering drugs such as tert-butyl 3-[5-ethyl-6-[4-(5,6,7,8-tetrahydro-(1,8)naphthyridin-2-yl)-piperidin-1-yl]-pyrimidin-4-ylamino]-2-(4-methoxy benzoyl)-propionate | GALAPAGOS SAS (FR) | 2010-12-07 | — | — | US | disclosed |
| US-7825119-B2 | Bone disorders such as osteoporosis, tumors and cardiovascular disorders; 4-(2-carboxy-2-Boc-aminoethylamino)-6-piperidinopyrimidines such as tert-butyl 2-benzyloxycarbonylamino-3-[2,5-dimethoxy-6-(4-[1,8]naphthyridin-2-yl-piperidin-1-yl)pyrimidin-4-ylamino]-propionate | GALAPAGOS SAS (FR) | 2010-11-02 | — | — | US | disclosed |
| US-20100041675-A1 | treatment of retinopathy comprising administering drugs such as tert-butyl 3-[5-ethyl-6-[4-(5,6,7,8-tetrahydro-(1,8)naphthyridin-2-yl)-piperidin-1-yl]-pyrimidin-4-ylamino]-2-(4-methoxy benzoyl)-propionate | GALAPAGOS SAS | 2010-02-18 | — | — | US | disclosed |
| US-20080058348-A1 | Bone disorders such as osteoporosis, tumors and cardiovascular disorders; 4-(2-carboxy-2-Boc-aminoethylamino)-6-piperidinopyrimidines such as tert-butyl 2-benzyloxycarbonylamino-3-[2,5-dimethoxy-6-(4-[1,8]naphthyridin-2-yl-piperidin-1-yl)pyrimidin-4-ylamino]-propionate | PROSKELIA SAS | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041675-A1 | treatment of retinopathy comprising administering drugs such as tert-butyl 3-[5-ethyl-6-[4-(5,6,7,8-tetrahydro-(1,8)naphthyridin-2-yl)-piperidin-1-yl]-pyrimidin-4-ylamino]-2-(4-methoxy benzoyl)-propionate | TBXA2R, GPR55, ADGRE5 | ITGB3 282/4885ITGAV 342/4885ITGB6 395/4885 |
| US-20110039867-A1 | PYRIMIDINE DERIVATIVES WHICH ARE ANTAGONIST OF THE VITRONECTIN RECEPTOR | P2RY1, P2RY2, P2RX5 | ITGB3 273/4885ITGAV 492/4885ITGB6 376/4885 |
| US-20120115883-A1 | PYRIMIDINE DERIVATIVES WHICH ARE ANTAGONISTS OF THE VITRONECTIN RECEPTOR | P2RY1, P2RY2, P2RX5 | ITGB3 248/4885ITGAV 455/4885ITGB6 335/4885 |
| US-20080058348-A1 | Bone disorders such as osteoporosis, tumors and cardiovascular disorders; 4-(2-carboxy-2-Boc-aminoethylamino)-6-piperidinopyrimidines such as tert-butyl 2-benzyloxycarbonylamino-3-[2,5-dimethoxy-6-(4-[1,8]naphthyridin-2-yl-piperidin-1-yl)pyrimidin-4-ylamino]-propionate | CALCR, PTH1R, CALCRL | ITGB3 356/4885ITGAV 707/4885ITGB6 434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.